Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone

Investigational New Drugs

Volumn 25, Issue 3, 2007, Pages 187-195

  Cavalletti, Ennio ^a   Crippa, Luca ^a   Mainardi, Patrizia ^a   Oggioni, Norberto ^a   Cavagnoli, Rosanna ^a   Bellini, Ornella ^a   Sala, Franca ^a  

^a CTI Europe Srl   (Italy)

Author keywords

Anthracenedione; Anthracycline; Cardiomyopathy; Cardiotoxic; Pixantrone

Indexed keywords

ANTHRAQUINONE DERIVATIVE; BBR 2778; DOXORUBICIN; MITOXANTRONE; PIXANTRONE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; HEART; ISOQUINOLINES; MICE; MITOXANTRONE; MYOCARDIUM; TIME FACTORS;

EID: 34248642248     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9037-8     Document Type: Article

References (15)

1. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677
2. van Dalen EC, van der Pal HJ, Bakker PJ, Caron HN, Kremer LC (2004) Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer 40:643-652
3. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314
4. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717
5. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869-2879
6. Beggiolin G, Crippa L, Menta E, Manzotti C, Cavalletti E, Pezzoni G, Torriani D, Randisi E, Cavagnoli R, Sala F, Giuliani FC, Spinelli S (2001) Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 87:407-416
7. Corbett TH, Griswold DP Jr, Roberts BJ, Schabel FM Jr (1981) Absence of delayed lethality in mice treated with aclacinomycin A. Cancer Chemother Pharmacol 6:161-168
8. Herbrecht R, Borchmann P, Wilhelm M, Morschhauser F, Hess G, Kutz K, Comis S, Laffranchi BL, Engert A. Preliminary phase II study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. Blood 104:Abstract 2489
9. Bertazzoli C, Bellini O, Magrini U, Tosana MG (1979) Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep 63:1877-1883
10. Bellini O, Tosana MG, Bertazzoli C (1984) Comparison of the cardiotoxicity of anthracyclines in two experimental models in mice. Drugs Exp Clin Res X:91-95
11. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19:191-196
12. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677
13. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID (2003) Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 97:1991-1998
14. Jensen BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13:699-709
15. Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, Sabbah A, Woronoff-Lemsi MC, Cahn JY (2003) Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 14:277-281